ADUS Addus HomeCare Corporation - Common Stock

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

When examining a long-term compounder, astute market participants look past quarterly headlines to evaluate core operational drivers, margin stability, and pricing power. Addus HomeCare (NASDAQ:ADUS) embodies many classic characteristics of a durable portfolio holding: a sticky, non-franchise personal care delivery model, consistent organic growth, and a disciplined approach to capital allocation across fragmented regional markets. […]

Addus HomeCare (ADUS) heads into its 2026 Jefferies Healthcare Services and Technology Conference appearance with fresh attention on its AccentCare personal care acquisition and the stock’s recent sector driven move. After a strong run that produced a 23.45% 90 day share price return and lifted year to date share price gains to 8.73%, Addus HomeCare has seen momentum cool slightly in the last week as investors weigh the AccentCare deal, evolving Medicaid headlines, and the stock’s longer term...

Addus HomeCare' (ADUS) $275 million acquisition of AccentCare's personal care division will likely s

Healthcare stocks advanced late Monday afternoon, with the NYSE Healthcare Index up 1.5% and the Sta

Addus HomeCare (ADUS) agreed to acquire AccentCare's personal care operations outside of New York in

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

Addus HomeCare's (ADUS) exposure to Medicaid funding pressures is expected to be offset by potential

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

BrightSpring Health Services has surged 54% YTD on specialty pharmacy, infusion and EBITDA growth, but premium valuation and policy headwinds remain.

BrightSpring Health Services is gaining acute infusion share with 20%+ volume growth, targeting 12-15 new states in a $20 billion market.

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.

Its deepest fall inside a market shock is not its deepest fall, and that gap is what a holder should size for.

Addus HomeCare Q2 results and what they mean for the stock Addus HomeCare (ADUS) drew attention after reporting Q2 2026 results that showed revenue in line with expectations alongside an earnings per share beat. For investors, that mix raises fresh questions about how the stock reflects its fundamentals. The share price of Addus HomeCare has eased slightly in the short term, with the 1-day, 7-day and 30-day share price returns all down modestly, even after a strong 90-day share price return...

Addus HomeCare stock has delivered a 34.6% gain over the past three years, while a fresh intrinsic value estimate suggests the current price may still sit below what its future cash flows imply. The market price near US$118 puts investors between a strong historical return and an analytical view that points to possible undervaluation. A 34.6% share price gain over three years shows that Addus HomeCare has already rewarded patient investors, so the question is how much of the long term...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the senior health, home health & hospice industry, including Addus HomeCare (NASDAQ:ADUS) and its peers.

Over the past six months, Addus HomeCare has been a great trade, beating the S&P 500 by 5.7%. Its stock price has climbed to $121.14, representing a healthy 16.5% increase. This performance may have investors wondering how to approach the situation.

Investors need to pay close attention to ADUS stock based on the movements in the options market lately.

The gap between its revenue multiple and its cash multiple is margin, and the company is spending it on purpose.

Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?

ADUS vs. ELAN: Which Stock Is the Better Value Option?

Here is how Novavax (NVAX) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.

Addus HomeCare (ADUS) reported impressive Q2 organic growth across its core personal care and hospic

Addus HomeCare Corp (ADUS) reports 8% revenue growth and 16.1% adjusted EPS increase, while navigating hospice Medicare cap accruals and home health segment challenges.

Addus HomeCare (NASDAQ:ADUS) reported second-quarter 2026 revenue growth of 8% and adjusted earnings-per-share growth of 16.1%, supported by expansion in personal care and hospice services, improved cash generation and ongoing acquisition activity. Total net service revenues rose to $377.4 million

Addus HomeCare Corporation has now reported its second-quarter and first-half 2026 results, with Q2 net income of US$27.61 million and diluted EPS from continuing operations of US$1.49, both higher than the same periods in 2025. Alongside this, the company’s non-GAAP earnings per share modestly outpaced analyst expectations while maintaining an 11.5% adjusted operating margin, underscoring consistent profitability on essentially flat margins year over year. We’ll now examine how this...

Addus HomeCare (ADUS) attracted fresh attention after its Q2 2026 results, which matched Wall Street revenue expectations. Non-GAAP earnings per share and operating margins came in slightly ahead and remained steady year on year. See our latest analysis for Addus HomeCare. At a share price of $116.79, Addus HomeCare has seen a 30-day share price return of 11.05% and a 90-day share price return of 20.85%. The 1-year total shareholder return of 0.19% suggests recent momentum is building off a...

The headline numbers for Addus HomeCare (ADUS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Addus HomeCare (ADUS) delivered earnings and revenue surprises of +2.37% and +0.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Home healthcare provider Addus HomeCare (NASDAQ:ADUS) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8% year on year to $377.4 million. Its non-GAAP profit of $1.73 per share was 1.9% above analysts’ consensus estimates.

Home healthcare provider Addus HomeCare (NASDAQ:ADUS) will be reporting results this Monday after market hours. Here’s what you need to know.

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.

The telehealth company is making a bold pivot that's driving growth, but the stock's recent slide has investors wondering if the price of admission is still too high.

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

Addus HomeCare Corporation (NASDAQ:ADUS) is one of the best small cap stocks to buy with the highest upside potential. Barclays lifted the price target on Addus HomeCare Corporation (NASDAQ:ADUS) to $96 from $92 on July 8 and maintained an Underweight rating on the shares. The firm adjusted price targets among its U.S. healthcare facilities and managed […]